Urine test could help to guide treatment of bladder cancer
the ONA take:
According to new research published in the British Journal of Cancer, researchers at the University of Birmingham in Birmingham, United Kingdom, have identified two prognostic urinary biomarkers, epidermal growth factor receptor (EGFR) and epithelial cell adhesion molecule (epCAM), that could help to guide clinicians in the treatment of patients with bladder cancer.
In the study, researchers found that both urinary EGFR and EpCAM were found to be independent predictors of bladder cancer-specific survival when validated in over 400 clinical samples. In addition, both have prognostic value over any standard clinical and pathological observations. Results showed that higher levels of the biomarkers were associated with more aggressive cases of cancer and poor survival outcomes.
The researchers note that a non-invasive prognostic test could make treatment of the disease much more efficient, allow for a refinement of surveillance strategies according to risk, and reduce visits to a clinician. The authors point out that these biomarkers cannot be utilized to diagnose bladder cancer.
The American Cancer Society estimates that there will be about 74,000 new cases of bladder cancer diagnosed in the United States in 2015 and about 16,000 deaths from the disease.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|